Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
149
40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
K and S Professional Research Services
Little Rock, Arkansas, United States
Synergy Clinical Research of Escondido
Escondido, California, United States
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States
Pacific Research Partners, LLC
Oakland, California, United States
California Clinical Trials
Paramount, California, United States
Adverse Events
Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.
Time frame: 6 months
Efficacy
Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pasadena Research Institute
Pasadena, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC
Pico Rivera, California, United States
California Neuropsychopharmacology Clinical Research Institute (CNRI)
San Diego, California, United States
University of California San Diego Medical Center
San Diego, California, United States
Collaborative Neuroscience Network, South Bay
Torrance, California, United States
...and 17 more locations